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Regression of extramedullary hematopoiesis with hydroxyurea therapy in
β-thalassemia intermedia
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Introduction
Extramedullary hematopoiesis (EMH) is a compensatory
mechanism that occurs in patients with hematological
dysfunctions, such as thalassemia major or intermedia and
sickle cell anemia.1 EMH most commonly occurs in organs
that have physiological hematopoiesis during embryonic life,
especially the liver, spleen and lymph nodes.2 Other less
frequent locations of diffuse compensatory EMH are the
kidneys, adrenal glands, breasts, spinal cord, pleura, peri-
cardium, duramater, adipose tissue and skin. Intrathoracic
extramedullary hematopoiesis is a rare condition.2,3
Transfusions have been successful in reducing EMH
in patients with thalassemia intermedia. On the other hand,
hydroxyurea (HU), an inhibitor of the cellular enzyme
ribonucleotide reductase, has been associated with clinical
improvement in sickle cell anemia, but there is limited
experience with HU in thalassemia.4,5
We present a case of regression of intrathoracic EMH
with HU therapy in a patient with β-thalassemia intermedia.
Case report
A 39-year-old woman with β-thalassemia intermedia
(genotype IVS1-6/ IVS1-110) was asymptomatic when she
suffered a traumatic break of her left scapula. The whole
blood count was as follows: hemoglobin 8.8 g/dL; hematocrit
28.0%; mean corpuscular volume 77.0 fl; mean corpuscular
hemoglobin 24.0 pg; leukocytes 9.4 x109/L; platelets 635
x109/L. A chest X-ray demonstrated that there was a break
of left scapula and also it showed a middle-lower mediastinal
mass.
A thoracic computed tomography (CT) showed a right
smoothly-bordered paravertebral mass located on the T3 -
T9 levels without bone destruction (Figure 1). The patient
was treated with HU at an initial dose of 8.5 mg/Kg/day,
with the dose increased every 8 weeks to a final dose of
16.0 mg/Kg/day.
A follow-up CT was obtained one and two years later
with EMH regression (Figure 2). There were no side effects
during HU treatment.
Excessive ineffective erythropoiesis in thalassemia intermedia may cause extramedullary
hematopoiesis (EMH), resulting in spleen and liver enlargement or masses in several
tissues, mainly paravertebrally. Other less frequent locations of diffuse compensatory
EMH are kidneys, adrenal glands, breasts, spinal cord, pleura, pericardium, duramater,
adipose tissue and skin, although intrathoracic extramedullary hematopoiesis is a rare
condition. Management strategies have included radiation and transfusion therapy.
Hydroxyurea with transfusion therapy has been associated with clinical regression of
EMH in thalassemia. We report an uncommon case of intrathoracic EMH in a patient
with β-thalassemia intermedia, that showed significant recovery with HU therapy. Rev.
bras. hematol. hemoter. 2006;28(1):71-72.
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Discussion
Excessive ineffective erythropoiesis in thalassemia
intermedia may cause EMH, resulting in spleen and liver
enlargement or masses in several positions, specifically
paravertebrally.
Management strategies have included radiotherapy,
blood transfusions and, occasionally, surgery.1,2 Spontaneous
recovery with no therapeutic intervention has also been
reported, but may take several months to occur and is subject
to frequent recurrence.6
HU has been associated with increase of the total
percentage of fetal hemoglobin and the number of F-cells, as
well as the total hemoglobin concentration and mean
corpuscular volume in sickle cell patients.7 Although there is
limited experience with HU in thalassemia, some studies have
demonstrated successful regression of EMH with HU
therapy.4,5,7
Our report calls attention to the fact that asymptomatic
EMH patients may have important clinical improvement with
conservative therapy such as HU. However, prospective
studies to define influence factors to response and rate of
EMH recurrence after HU use are necessary.
Resumo
A  excessiva eritropoese ineficaz na talassemia pode causar hemato-
poese extramedular (HEM), resultando em hepatomegalia,
esplenomegalia e massas de tecido hematopoético em diversos teci-
dos. Localizações de HEM compensatória menos freqüentes são
rins, glândulas adrenais, canal medular, pleura, pericárdio,
duramáter, tecido adiposo e pele. Entretanto, HEM intratorácica é
condição rara. Estratégias terapêuticas incluem radiação e trans-
fusões sanguíneas. O uso de hidroxiuréia concomitante a terapêu-
tica transfusional foi associado à regressão clínica da HEM na
talassemia. Nós descrevemos um caso de HEM intratorácica em
paciente portadora de talassemia intermédia, com significante re-
gressão do quadro após terapêutica isolada com hidroxiuréia. Rev.
bras. hematol. hemoter. 2006;28(1):71-72.
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talassemia; hidroxiuréia.
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Figure 1. Thoracic computed tomography with right paravertebral
mass without bone destruction
Figure 2.  Follow-up thoracic computed tomography after hydroxyurea
therapy with reduction of paravertebral mass
